Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Cancer: Screening

Department of Health and Social Care written question – answered on 17th October 2018.

Alert me about debates like this

Photo of Nicholas Dakin Nicholas Dakin Opposition Whip (Commons)

To ask the Secretary of State for Health and Social Care, for what reason the tumour profiling test Oncotype DX has not been included in NHS England’s National Genomic Test Directory.

Photo of Nicholas Dakin Nicholas Dakin Opposition Whip (Commons)

To ask the Secretary of State for Health and Social Care, what the NHS commissioning pathway is for the tumour profiling test Oncotype DX which is used for certain breast cancer patients.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) published diagnostics guidance in 2013 on the use of gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management, including Oncotype DX. NICE’s guidance recommends Oncotype DX subject to specific clinical criteria to help make decisions about chemotherapy after surgery in some people with oestrogen receptor positive (ER+), lymph node negative (LN−) and human epidermal growth factor receptor 2 negative (HER2−) early breast cancer.

NHS England will be reflecting the 2013 NICE guidelines related to Oncotype DX in the National Genomic Test Directory for cancer. However it is important to note that the NICE guidance relating to this intervention is under review and once a decision has been made by NICE, this information will be considered as part of the regular review and update of the Test Directory.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.